Ischemic Stroke
Conditions
Keywords
Ischemic Stroke
Brief summary
That the Jan Medical Nautilus NeuroWaveTM system provides significantly higher sensitivity to hyper acute ischemic stroke than does CT.
Detailed description
In spite of the fact that approximately 800,000 strokes are diagnosed in the United States each year, many physicians and patients have approached the management of stroke with a sense of futility. However, within the past 2 decades, following the advent of computerized tomography (CT), medical interest has turned toward stroke and effective interventions to treat and prevent it have received attention. CT and/or magnetic resonance imaging (MRI) are the typical diagnostic tools used in the event of a stroke alert. These studies are done on an emergent or urgent basis, since, to be effective, treatments for ischemic and hemorrhagic stroke must be delivered soon after onset of the illness. In an effort to institute an appropriate therapeutic regime, laboratory and structural diagnostic studies are required to be done as rapidly as possible to determine pathological etiology, size, and location of concern. The speed at which a diagnosis is made and a treatment plan established often determines patient outcome and any associated complications. This is especially true when evaluating patients for ischemic stroke where there is a narrow 3 hour window of opportunity in which to resolve the clot with IV .before permanent neurological impairment results, and up to 8 additional hours with the use if intra arterial (IA) t-PA or interventional mechanical embolectomy procedures are utilized. Current treatment modalities include pharmacologic thrombolytic drugs utilized to disrupt or dissolve clots located in the distal vasculature or mechanical intervention in larger vessels. Since many patients do not recognize the symptoms of stroke they do not seek medical attention immediately. Significant time is then often lost from the onset of the stroke before seeking medical help / treatment. Although the current technologies are quite adequate as diagnostic tools for hemorrhagic stroke and for identifying subdural hematomas, and other pooled blood abnormalities which would preclude t-PA therapy, they are largely ineffective at positively identifying stroke during the limited therapeutic window of time. Positive identification of ischemia itself is rarely possible or practical with CT or within the limited therapeutic window. As such the diagnostic determination and associated treatment decisions are based on the unsatisfactory basis of exclusion.
Interventions
Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
Sponsors
Study design
Eligibility
Inclusion criteria
* Symptoms consistent with stroke with known onset \< 12 hours prior to enrollment and planned recording with the Nautilus NeuroWave System * Suspected pathology of following vessels: internal carotid artery, ACA, MCA, PCA, basilar or other anterior or posterior cerebral vessels or normal anatomy * Subject is planned to undergo standard stroke triage imaging protocol * Able to understand and provide signed informed consent, or have a Legally Authorized Representative willing to provide informed consent on subject's behalf
Exclusion criteria
* Known to meet hospital criteria for brain death * Not a candidate for CT, MRI * unknown time of stroke symptom onset. * Psychologically unstable and not able to cooperate * Not suitable for participation in this study in the opinion of the Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Device Related Adverse Events | 2-3 days, at subject exit (variation of subject exit date depended on when subject obtained their radiology imaging to confirm ischemic stroke) | Count the number of participants with device related adverse events |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Nautilus NeuroWave Recording Arm Nautilus NeuroWaveTM System
Nautilus NeuroWaveTM System: Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke. | 29 |
| Total | 29 |
Baseline characteristics
| Characteristic | Nautilus NeuroWave Recording Arm |
|---|---|
| Age, Continuous | 55.3 years STANDARD_DEVIATION 16.2 |
| Region of Enrollment United States | 29 participants |
| Sex/Gender, Customized Females Known | 16 participants |
| Sex/Gender, Customized Gender Unknown | 6 participants |
| Sex/Gender, Customized Males Known | 7 participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 29 |
| serious Total, serious adverse events | 0 / 29 |
Outcome results
Number of Participants With Device Related Adverse Events
Count the number of participants with device related adverse events
Time frame: 2-3 days, at subject exit (variation of subject exit date depended on when subject obtained their radiology imaging to confirm ischemic stroke)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nautilus NeuroWave Recording Arm | Number of Participants With Device Related Adverse Events | 0 Participants |